Zibb.com: Abbott Laboratories (Industry News & Blogs)

Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochem...

Tue, 17 Nov 2009 06:00:00 GMT

Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platform

Abbott Laboratories Reports Positive Results on Niaspan

Mon, 16 Nov 2009 22:36:38 GMT

Abbott Laboratories (ABT) announced on Monday positive results of cholesterol drug Niaspan.

PanGenetics signs agreement with Abbott Laboratories for PG110 - ...

Fri, 13 Nov 2009 14:01:03 GMT

PanGenetics B.V., a Netherlands-based antibody development company, has entered into an agreement with Abbott Laboratories, under which Abbott will acquire the global rights to a nerve growth factor humanized antibody, PG110. Abbott is a US-based company engaged in the discovery, development,

Abbott Laboratories initiated with "outperform"

Thu, 12 Nov 2009 18:12:36 GMT

NEW YORK, November 12 (newratings.com) - Analysts at Wedbush Morgan initiate coverage of Abbott Laboratories (ticker: ABT) with an "outperform" rating. The target price is set to $62. [more]

[$$] Abbott Labs Is Making the Right Moves (at Barrons.com)

Thu, 12 Nov 2009 17:47:12 GMT

Dow Jones Reprints: This copy is for your personal, non-commerical use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool on any article or visit www.djreprints.com

Abbott Labs leads drug stocks higher

Thu, 15 Oct 2009 14:38:16 GMT

Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory

Abbott Laboratories posts solid earnings results

Wed, 14 Oct 2009 17:00:00 GMT

Filed under: Earnings reports, Forecasts, Abbott Laboratories

Abbott Labs leads drug stocks higher

Wed, 14 Oct 2009 13:52:37 GMT

BOSTON (MarketWatch) -- Abbott Laboratories led drug stocks into positive territory early Wednesday as shares of the conglomerate gained in the wake of a positive third-quarter earnings report. The NYSE Arca Pharmaceutical Index climbed 0.5% to 291.23 as the NYSE Arca Biotechnology Index rose 1% to

Earnings Preview: Abbott Labs

Tue, 13 Oct 2009 18:10:40 GMT

Abbott Labs (ABT) is expected to report Q3 earnings Wednesday, October 14 before market open, with a conference call scheduled for 9 am ET.

Earnings Preview: Abbott Laboratories - Yahoo! Finance

Mon, 12 Oct 2009 15:48:03 GMT

WASHINGTON (AP) -- Drug and medical-device company Abbott Laboratories is scheduled to report earnings for the third quarter on Wednesday. The following is a summary of

Earnings Preview: Abbott Laboratories | R&D Mag

Mon, 12 Oct 2009 15:26:07 GMT

Abbott Laboratories reports 3rd-quarter earnings following Solvay acquisition

Earnings Preview: Abbott Laboratories

Mon, 12 Oct 2009 15:05:22 GMT

Drug and medical-device company Abbott Laboratories is scheduled to reports earnings for the third quarter on Wednesday. The following is a summary of key developments and analyst opinion related to the period.

Abbott Laboratories / Solvay

Mon, 28 Sep 2009 21:39:55 GMT

Its best-selling drug, the TriCor cholesterol treatment, sold in partnership with Abbott, faces a threat from generic competition as of 2011. Operating margins of about 18 per cent are also below the 25 per cent typical of a speciality pharma company.

FDA approves new HIV test from Abbott Laboratories

Fri, 18 Sep 2009 21:25:52 GMT

HIV attacks the body's immune system, eventually causing AIDS. Just over 1.1 million Americans are estimated to have HIV and 232,000 do not know it, according to the Centers for Disease Control and Prevention.

OSHA and Abbott Labs team up for healthcare safety

Wed, 19 Aug 2009 07:25:05 GMT

Agreement calls for developing information and increasing access to training resources

industrialinfo.com - Negative Foreign Exchange Hurts Abbott Labor...

Fri, 17 Jul 2009 00:00:00 GMT

Net earnings for the company were down 2.6% from 2Q08, moving from $1.32 billion last year to $1.29 billion this year.

Abbott profit dips on charges, generic competition

Wed, 15 Jul 2009 18:50:58 GMT

(AP Photo/Abbott Laboratories) FILE - In this July 13, 2005 file photo provided by Abbott Laboratories, the North Chicago-based company's rheumatoid arthritis therapy Humira, is shown.

Blockbuster drug Humira helps Abbott Laboratories meet forecasts

Wed, 15 Jul 2009 13:07:00 GMT

Sorry for the inconvenience."); console.log('Gallery error status: '+textStatus+ ' Error thrown: '+errorThrown); } }); } } art.showTab = function(event, ui, content, wideTab) { var content = ui.tab.hash.split('#')[1]; // ie. photos, article, comments, interactive art.

Abbott Laboratories Profit Falls 3%; Shares Lower

Wed, 15 Jul 2009 00:00:00 GMT

Abbott Laboratories' second-quarter earnings fell 2.6 percent, with generic competition for its Depakote anti-seizure drug overshadowing strong sales of its Humira arthritis drug and its Xience heart stent.

Zacks Bull & Bear of the Day Highlights: Johnson & Johnson, BJ Se...

Tue, 31 Mar 2009 10:30:16 GMT

Zacks Bull & Bear of the Day Highlights: Johnson & Johnson, BJ Services, Saks, Wal-Mart and LeapFrog Enterprises

NVIDIA revs up pro graphics lineup

Mon, 30 Mar 2009 15:44:00 GMT

List of Authorized Generic Drugs

Fri, 27 Mar 2009 11:40:00 GMT

Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs).

Abbott Labs Buys Medical Products Maker

Mon, 12 Jan 2009 14:01:08 GMT

Abbott will pay about $1.36 billion plus debt for Advanced Medical Optics in an effort to expand its eye care offerings.

Stock index futures mixed ahead of last 2008 session (Reuters)

Wed, 31 Dec 2008 09:28:01 GMT

Stock index futures pointed to a mixed open on Wall Street on Wednesday, ahead of the last trading session of what has been a torrid year for stock markets worldwide. News, Headlines and Latest Stories on Yahoo! News

Best Stock for 2009: Somanetics (at Motley Fool)

Thu, 18 Dec 2008 16:26:31 GMT

Good riddance to 2008, and welcome to 2009. We, the investing populace, scarred by the past year's bludgeoning, are desperate for places to park our money. But where?